Logo for Novartis AG

Novartis Investor Relations Material

Latest events

Logo for Novartis AG

AGM 2024

Logo for Novartis

AGM 2024

5 Mar, 2024
Logo for Novartis

Q4 2023

31 Jan, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Novartis AG

Access all reports
Segment Data
Access more data
Net sales by
Business area
Innovative Medicines
Expenses by

Swiss Pharmaceuticals

Novartis International AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Established in 1996 through the merger of two companies, Novartis has cemented its place as one of the world's largest and most influential pharmaceutical companies with operations in over 150 countries. The company's portfolio includes a range of medicines, generic drugs, eye care devices, and consumer health products.

Roots in Swiss Pharmaceutical Companies

Novartis can trace its roots in two Swiss chemical companies, Ciba-Geigy and Sandoz, which had both been active in the global pharmaceutical industry for over a century before their merger. The fusion in 1996 aimed to leverage their combined strength in research and development, resulting in a global pharmaceutical behemoth. Novartis has since consistently ranked among the largest healthcare companies globally, partly due to its strong commitment to the development of new treatments.

A Diversified Pharmaceutical Powerhouse

Novartis operates under three main divisions: Innovative Medicines, Sandoz (generics), and Alcon (eye care). The Innovative Medicines division also referred to as the pharmaceuticals division, is dedicated to developing, manufacturing, and marketing patented prescription drugs. It includes two business units: Novartis Oncology and Novartis Pharmaceuticals, which target various therapeutic areas, including oncology, cardiology, respiratory, neuroscience, and ophthalmology, to name a few. Sandoz, the generics division of Novartis, provides high-quality, affordable medicines that treat some of the most prevalent healthcare issues. Lastly, the Alcon division focuses on eye care, manufacturing medical devices and products for eye care professionals and patients. They operate in the same field as companies such as Roche, Sanofi, Pfizer, and other large pharmaceutical companies.

Keeping Up With the Times

While remaining at the forefront of pharmaceutical innovation, Novartis continuously aims to refine its product portfolio and adapt to the ever-evolving healthcare landscape. The company has made significant strides in gene and cell therapies, most notably with Kymriah, a CAR-T cell therapy for certain types of blood cancers. Moreover, Novartis is working in digital health, employing data science and digital technologies to aid in drug discovery, patient care, and even the way clinical trials are conducted. The goal is to make treatments more personalized and more efficient, further enhancing patient outcomes.